Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The utility of PD-L1 as a prognostic marker in pancreatic ductal adenocarcinoma (PDAC).
Authors
Linda Wu
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;
Linda Wu , Daniel Jeremy Fulop , Michelle Rudshteyn , Nagma Shah , Michael Hill-Oliva , Sophie Sohval , Sonal Gandhi , Nobel Chowdhury , Neha Debnath , Deirdre Jill Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 753)
DOI
10.1200/JCO.2023.41.4_suppl.753
Abstract #
753
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
First Author: Karam Ashouri
Poster
2022 ASCO Annual Meeting
Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network.
First Author: Katherine E Poruk
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti